Literature DB >> 25513779

In-vivo longitudinal MRI study: an assessment of melanoma brain metastases in a clinically relevant mouse model.

Mariama N Henry1, Yuhua Chen, Catherine D McFadden, Felicia C Simedrea, Paula J Foster.   

Abstract

Brain metastases are an important clinical problem. Few animal models exist for melanoma brain metastases; many of which are not clinically relevant. Longitudinal MRI was implemented to examine the development of tumors in a clinically relevant mouse model of melanoma brain metastases. Fifty thousand human metastatic melanoma (A2058) cells were injected intracardially into nude mice. Three Tesla MRI was performed using a custom-built gradient insert coil and a mouse solenoid head coil. Imaging was performed on consecutive days at four time points. Tumor burden and volumes of metastases were measured from balanced steady-state free precession image data. Metastases with a disrupted blood-tumor barrier were identified from T1-weighted spin echo images acquired after administration of gadopentetic acid (Gd-DTPA). Metastases permeable to Gd-DTPA showed signal enhancement. The number of enhancing metastases was determined by comparing balanced steady-state free precession images with T1-weighted spin echo images. After the final imaging session, ex-vivo permeability and histological analyses were carried out. Imaging showed that both enhancing and nonenhancing brain metastases coexist in the brain, and that most metastases switched from the nonenhancing to the enhancing phenotype. Small numbers of brain metastases were enhancing when first detected by MRI and remained enhancing, whereas other metastases remained nonenhancing to Gd-DTPA throughout the experiment. No clear relationship existed between the permeability of brain metastases and size, brain location and age. Longitudinal in-vivo MRI is key to studying the complex and dynamic processes of metastasis and changes in the blood-tumor barrier permeability, which may lead to a better understanding of the variable responses of brain metastases to treatments.
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25513779     DOI: 10.1097/CMR.0000000000000136

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  7 in total

Review 1.  The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.

Authors:  Costas D Arvanitis; Gino B Ferraro; Rakesh K Jain
Journal:  Nat Rev Cancer       Date:  2019-10-10       Impact factor: 60.716

2.  Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer.

Authors:  Ramakrishna Samala; Helen R Thorsheim; Satyanarayana Goda; Kunal Taskar; Brunilde Gril; Patricia S Steeg; Quentin R Smith
Journal:  Pharm Res       Date:  2016-08-19       Impact factor: 4.200

Review 3.  The blood-tumour barrier in cancer biology and therapy.

Authors:  Patricia S Steeg
Journal:  Nat Rev Clin Oncol       Date:  2021-07-12       Impact factor: 66.675

4.  Comparing the fate of brain metastatic breast cancer cells in different immune compromised mice with cellular magnetic resonance imaging.

Authors:  Natasha N Knier; Amanda M Hamilton; Paula J Foster
Journal:  Clin Exp Metastasis       Date:  2020-06-12       Impact factor: 5.150

Review 5.  Current landscape and future perspectives in preclinical MR and PET imaging of brain metastasis.

Authors:  Synnøve Nymark Aasen; Heidi Espedal; Olivier Keunen; Tom Christian Holm Adamsen; Rolf Bjerkvig; Frits Thorsen
Journal:  Neurooncol Adv       Date:  2021-10-14

Review 6.  Preclinical Models of Brain Metastases in Breast Cancer.

Authors:  Natasha N Knier; Sierra Pellizzari; Jiangbing Zhou; Paula J Foster; Armen Parsyan
Journal:  Biomedicines       Date:  2022-03-13

7.  A novel molecular magnetic resonance imaging agent targeting activated leukocyte cell adhesion molecule as demonstrated in mouse brain metastasis models.

Authors:  Niloufar Zarghami; Manuel Sarmiento Soto; Francisco Perez-Balderas; Alexandre A Khrapitchev; Christina Simoglou Karali; Vanessa A Johanssen; Olaf Ansorge; James R Larkin; Nicola R Sibson
Journal:  J Cereb Blood Flow Metab       Date:  2020-11-05       Impact factor: 6.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.